Bariendo and Fractyl Health Plan for Potential GLP-1 Off-Ramp Program Pending FDA Approval of Revita

The obesity crisis isn’t slowing down, and neither are we in our efforts to bring the latest medical technology and treatments to patients.

Today, we’re proud to announce a new partnership between Bariendo and Fractyl Health, focused on an underserved need in obesity care: sustainable weight maintenance after GLP-1 medications.

GLP-1s have transformed the treatment landscape for obesity and diabetes, helping millions lose weight and lower their risk of chronic disease. But the challenge is what comes next: Most patients regain the weight after stopping the medication, or take it indefinitely—an expensive path that often comes with ongoing side effects.

That’s where this partnership comes in.

What is Revita?

Revita® is Fractyl’s promising investigational outpatient endoscopic procedure that targets the root causes of obesity at the level of the gut. By resurfacing the mucosal lining of the duodenum (the first part of the small intestine), Revita aims to reset key nutrient sensing and signaling mechanisms that become disrupted in people with obesity. This disruption, often driven by high-fat and high-sugar diets, can lead to weight gain and metabolic disease. Revita’s potential as a disease-modifying therapy could make it one of the first interventions with an indication for post-GLP-1 weight maintenance—addressing a critical unmet need in obesity care.

Bariendo will serve as a future provider of choice for Revita, integrating it into our concierge model of endoscopic care, nutrition support, and long-term follow-up. As part of this partnership, Bariendo is committed to ensuring operational readiness for Revita when it becomes available, including designing a companion program to support patients in transitioning from GLP-1 therapy to Revita-based weight maintenance.

Future of Obesity Care

At Bariendo, we believe in the power of advanced non-surgical, minimally invasive endoscopic procedures to “upgrade” the GI tract and tackle obesity in a durable way. This partnership reflects our vision for the future of obesity care: durable, personalized, and focused on whole-patient outcomes.

Together with Fractyl Health, we are paving the way for a science-backed, non-pharmaceutical off-ramp from GLP-1s—giving patients a better chance at long-term health and freedom from chronic medication use.

This is the future of obesity care, powered by Bariendo.